Facioscapulohumeral Muscular Dystrophy (FSHD) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Facioscapulohumeral Muscular Dystrophy (FSHD) – Drugs In Development, 2024 report and make more profitable business decisions.
Facioscapulohumeral muscular dystrophy (FSHD) typically manifests with varying degrees of facial, scapular stabilizer, and dorsiflexor muscle weakness. Progression is slow, with about 20% of individuals eventually requiring a wheelchair, though life expectancy remains unaffected. Diagnosis of FSHD1 involves identifying a heterozygous pathogenic contraction of the D4Z4 repeat array on chromosome 4q35 with a chromosome 4 permissive haplotype. FSHD2 diagnosis is established by detecting D4Z4 repeat array hypomethylation on chromosome 4q35 with the same haplotype, linked to heterozygous pathogenic variants in SMCHD1 or DNMT3B. Treatment addresses symptoms, involving physical therapy, orthoses, surgery for scapular fixation, pain management, respiratory function monitoring, and specific interventions for ocular, auditory, and other associated issues.
The Facioscapulohumeral Muscular Dystrophy (FSHD) drugs in development market research report provide comprehensive information on the therapeutics under development for Facioscapulohumeral Muscular Dystrophy (FSHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Facioscapulohumeral Muscular Dystrophy (FSHD) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Facioscapulohumeral Muscular Dystrophy (FSHD) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 24 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Facioscapulohumeral Muscular Dystrophy (FSHD) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Facioscapulohumeral Muscular Dystrophy (FSHD) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Altay Therapeutics IncArmatus Bio LLC
Arrowhead Pharmaceuticals Inc
Avidity Biosciences Inc
Celularity Inc
Children's National Hospital
Dyne Therapeutics Inc
ECM Therapeutics Inc
Epicrispr Biotechnologies Inc
F. Hoffmann-La Roche Ltd
Facio Therapies BV
Fred Hutchinson Cancer Research Center
Fulcrum Therapeutics Inc
Healx Ltd
Kate Therapeutics Inc
Myocea Inc
Nationwide Children's Hospital
Renogenyx Inc
Sanofi
Sarcomed AB
University of Minnesota
University of Montpellier
Vita Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Facioscapulohumeral Muscular Dystrophy (FSHD) reports